Skip to main content
logo
AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.58
-0.16 (-2.79%)
Aug 28, 2026, 4:00 PM EDT - Market closed

AN2 Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-36.28-35.17-51.32-64.73-40.96-21.54
Loss (Gain) From Sale of Investments
-0.5-1.07-3.28-2.86-0.690.05
Stock-Based Compensation
4.636.258.348.414.390.97
Other Operating Activities
---0.050.08-
Change in Accounts Payable
-0.5-0.30.640.552.50.42
Change in Other Net Operating Assets
1.960.46-3.645.281.22-0.39
Operating Cash Flow
-30.68-29.83-49.26-53.29-33.46-20.48
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Investment in Securities
17.9128.3154.59-43.28-21.77-50.02
Investing Cash Flow
17.9128.3154.59-43.28-21.77-50.02

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
39.110.110.3784.9970.370.01
Repurchase of Common Stock
-----0.01-
Other Financing Activities
-0.25-----1.21
Financing Cash Flow
38.870.110.3784.9970.3678.54

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
26.1-1.415.7-11.5715.128.03

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-18.02-18.38-29-28.85-19.3-11.96
Unlevered Free Cash Flow
-18.02-18.38-29-28.85-19.3-11.96

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1.460.16-35.833.720.03
SEC Filings: 10-K · 10-Q